Treatment of diffuse large B-cell lymphomas

Short review

Over 30 years ago, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was demonstrated to induce complete remissions and long-term disease-free survival in a considerable proportion of lymphoma patients. Since then many attempts to improve results by modifications of CHOP using escalated doses, additional drugs or the alternative use of putatively non-cross resistant chemotherapy regimens failed in randomized trials. While dose escalation strategies including high-dose approaches necessitating stem cell support have not yet unequivocally been demonstrated to be superior to a base-line CHOP-21, dose-dense bi-weekly modifications (CHOP-14) with growth factor support (G-CSF) improved the outcome of young and elderly patients with aggressive lymphomas compared to CHOP-21. A substantial improvement of treatment results has also been achieved by the implementation of rituximab into treatment protocols. Although not formally established in young patients with poor-prognosis, the combined immuno-chemotherapy with CHOP and rituximab has become an accepted standard for the treatment of diffuse large B-cell lymphoma (DLBCL) worldwide. For patients >60 years of age 6 courses CHOP-14 using G-CSF with rituximab (R-CHOP-14) followed by two additional courses of rituximab yielded the best treatment results without a relevant increase in toxicity compared with CHOP-21. For younger low-risk patients (aaIPI 0,1) 6 courses R-CHOP-21 are the standard treatment. Young high-risk patients (aaIPI ≥ 2) should be treated with dose-dense regimens within clinical trials.


Aggressivenon-Hodgkin’slymphoma chemotherapy immunotherapy clinical trials monoclonal antibody 


  1. 1.
    Pfreundschuh M, Truemper L, Oesterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P-L, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E and Loeffler M (2006). CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 7: 379–391 CrossRefPubMedGoogle Scholar
  2. 2.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med, 329: 987–994, 1993Google Scholar
  3. 3.
    Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C and Loeffler M (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626–633 CrossRefPubMedGoogle Scholar
  4. 4.
    Pfreundschuh M, Zeynalova S, Pflueger K-H, Koch P, Mergenthaler M, Bentz M, Schmitz N and Loeffler M (2006). Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: results of a randomized DSHNHL trial. J Clin Oncol 24(18s): 7513 Google Scholar
  5. 5.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY and Harousseau JL (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 1540–1545 CrossRefPubMedGoogle Scholar
  6. 6.
    Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P and Bonadonna G (1997). High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297 CrossRefPubMedGoogle Scholar
  7. 7.
    Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P and Reyes F (2000). Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18: 3025–3030 PubMedGoogle Scholar
  8. 8.
    Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, and Haak HL (1995). Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non- Hodgkin’s lymphoma. N Engl J Med 332: 1045–1051 CrossRefPubMedGoogle Scholar
  9. 9.
    Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L and Rizzoli V (1998). VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diff use non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 16: 2796–2802 PubMedGoogle Scholar
  10. 10.
    Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, Musson H, Teodorovic I, Maes B, Carbone A, Carde P and Thomas J (2001). Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93: 22–30 CrossRefPubMedGoogle Scholar
  11. 11.
    Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Muller P, Mantovani L, Grundeis M, Rothmann F, van Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Koppler H, Parwaresch R, Pfreundschuh M, Havemann K (2002). Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 20: 4413–4419 CrossRefPubMedGoogle Scholar
  12. 12.
    Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T and Coiffier B (1999). International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17: 423–429 PubMedGoogle Scholar
  13. 13.
    Glass B, Kloess M, Engert A, Berdel WE, Metzner B, Truemper L, Loeffler M, Pfreundschuh M and Schmitz N (2002). Mega-CHOEP repeated high dose therapy as treatment of aggressive NHL: critical impact of time scheduling. Blood, 100: 776a Google Scholar
  14. 14.
    Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N and Loeffler M (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104: 634–641 CrossRefPubMedGoogle Scholar
  15. 15.
    Pfreundschuh M, Kloess M, Zeynalova S, Lengfelder E, Franke A, Reiser M, Steinhauer H, Clemens M, Nickenig C, de Witt M, Metzner B, Hensel M, Mergenthaler HG, Liersch R, Duehrsen U, Balleisen L, Engelhardt M, Poeschel V, Schubert J, Truemper L, Schmitz N and Loeffler M (2006). Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma: results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 108: 64a–65a Google Scholar
  16. 16.
    Cullen M, Steven N, Billingham Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S and Stanley AL (2005). Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353: 988–998 CrossRefPubMedGoogle Scholar
  17. 17.
    Sonneveld van Putten WL, Holte H, Biesma D, Marwijk-Kooy M, Kramer M, Wijermans P, Steijaert M, Huijgens P and Eriksson M (2005). Intensified CHOP with rituximab for intermediate or high-risk non-Hodgkin’s lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma groups. Blood 106: 10a Google Scholar
  18. 18.
    Hagberg H, Gisselbrecht C. CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol, 17(Suppl 4): iv31-2, 2006.Google Scholar
  19. 19.
    El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie- Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F and Haioun C (2007). Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18(8): 1363–1368 CrossRefPubMedGoogle Scholar
  20. 20.
    Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB and Habermann TM (2008). Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26(30): 4952–4957 CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  1. 1.Klinik für Innere Medizin ISaarland University Medical SchoolHomburgGermany

Personalised recommendations